Take the anti-cancer drug Avastin, which was fast-tracked by the FDA years ago. It is primarily used to treat colon cancer, but is also prescribed now to treat nearly 18,000 women a year who are fighting the late stages of breast cancer. While Avastin doesn't cure the disease, it can and does significantly lengthen and improve the quality of a victim's last months. Perhaps to be expected, Avastin is also very expensive, costing up to $100,000 a year.
But now suddenly, despite the stringent objections being made by both the Susan G. Komen Foundation and the Ovarian Cancer National Alliance on behalf of patients, the FDA is considering removing Avastin from its approved drug list for breast cancer. Such a move would mean ending its coverage by both Medicare and the government program for low-income women.
Read the full story at Visiontoamerica.org